Bruce Joseph Shook net worth and biography

Bruce Shook Biography and Net Worth

Director of Neuronetics

Bruce J. Shook serves as Independent Director of the Company. Mr. Shook brings more than 30 years of medical device industry experience to the Company, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He currently serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics. Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed (NASDAQ: ABMD), where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation. Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Venarum Medical, the Penn State Research Foundation and Life Sciences Pennsylvania. He previously served as a Director at Surgiquest, Respicardia and CoTherix.

What is Bruce Joseph Shook's net worth?: The estimated net worth of Bruce Joseph Shook is at least $207,527.68 as of May 27th, 2021. Mr. Shook owns 52,672 shares of Neuronetics stock worth more than $207,528 as of April 2nd. This net worth evaluation does not reflect any other investments that Mr. Shook may own. Learn More about Bruce Joseph Shook's net worth.
How do I contact Bruce Joseph Shook?: The corporate mailing address for Mr. Shook and other Neuronetics executives is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. Neuronetics can also be reached via phone at (610) 640-4202 and via email at ir@neuronetics.com. Learn More on Bruce Joseph Shook's contact information.
Has Bruce Joseph Shook been buying or selling shares of Neuronetics?: Bruce Joseph Shook has not been actively trading shares of Neuronetics during the last ninety days. Most recently, Bruce Joseph Shook sold 7,797 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $5.30, for a transaction totalling $41,324.10. Learn More on Bruce Joseph Shook's trading history.
Who are Neuronetics' active insiders?: Neuronetics' insider roster includes Robert Cascella (Director), Sheryl Conley (Director), Stephen Furlong (CFO), Gregory Harper (VP), William Macan (VP), Bruce Shook (Director), and Keith Sullivan (CEO). Learn More on Neuronetics' active insiders.
Are insiders buying or selling shares of Neuronetics?: In the last twelve months, Neuronetics insiders bought shares 7 times. They purchased a total of 261,776 shares worth more than $277,669.60. In the last twelve months, insiders at the sold shares 12 times. They sold a total of 139,515 shares worth more than $430,285.36. The most recent insider tranaction occured on March, 4th when CFO Stephen Furlong sold 1,867 shares worth more than $8,364.16. Insiders at Neuronetics own 9.8% of the company. Learn More about insider trades at Neuronetics.
Information on this page was last updated on 3/4/2025.

Bruce Joseph Shook Insider Trading History at Neuronetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2021	Sell	7,797	$5.30	$41,324.10
5/27/2021	Sell	15,200	$13.35	$202,920.00	52,672

Bruce Joseph Shook Buying and Selling Activity at Neuronetics

Neuronetics Company Overview

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $3.94

$3.65

$4.07

50 Day Range

MA: $4.11

$2.39

$5.42

2 Week Range

Now: $3.94

$0.52

$5.92

Volume

1,141,278 shs

Average Volume

642,492 shs

Market Capitalization

$119.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07